Wed. Jun 23rd, 2021
Neurogenic Detrusor Overactivity Market

(Albany, US) DelveInsight has launched a new report on “Neurogenic Detrusor Overactivity Market Insights, Epidemiology, and Market Forecast-2030“.

DelveInsight’s “Neurogenic Detrusor Overactivity Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Neurogenic Detrusor Overactivity, historical and forecasted epidemiology as well as the Neurogenic Detrusor Overactivity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the Neurogenic Detrusor Overactivity Companies:

  • Astellas Pharma, Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical
  • Allergan, Plc
  • Mylan N.V.
  • Hisamitsu Pharmaceutical Co., Inc
  • Sanofi
  • Cogentix Medical, Inc.
  • And Many Others

Request for free sample report: https://www.delveinsight.com/sample-request/neurogenic-detrusor-overactivity-market

Scope of the report:

  • The Neurogenic Detrusor Overactivity report covers the descriptive overview of Neurogenic Detrusor Overactivity, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Neurogenic Detrusor Overactivity epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Neurogenic Detrusor Overactivity are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Neurogenic Detrusor Overactivity market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neurogenic Detrusor Overactivity market.

Request for free sample report: https://www.delveinsight.com/sample-request/neurogenic-detrusor-overactivity-market

Neurogenic detrusor overactivity, previously known as hyperreflexia, is increased or involuntary muscle contractions of the detrusor muscle in the bladder. It is a neurological condition causing urinary incontinence and is due to damage or disruption of the nerves supplying the detrusor muscle. Because of the increase in weight being carried during pregnancy, women can experience neurogenic detrusor overactivity before or after childbirth.

Physiotherapy is a very effective way of retraining the bladder and reducing the symptoms of neurogenic detrusor overactivity. At Physio.co.uk there are specialist women’s health physiotherapists who are experienced in assessing and treating neurogenic detrusor overactivity. Your physiotherapist will be able to provide you with a comprehensive treatment programme to manage your symptoms and facilitate a successful recovery.

There are a number of symptoms to look out that may be associated with neurogenic detrusor overactivity. It is important that you are able to identify these and begin physiotherapy treatment as soon as possible. Possible symptoms include:

  • Urge incontinence
  • Stress incontinence
  • More regular urination
  • Waking during the night to go to the toilet

Request for free sample report: https://www.delveinsight.com/sample-request/neurogenic-detrusor-overactivity-market

Table of Contents:

  1. Key Insights
  2. Executive Summary of Neurogenic Detrusor Overactivity
  3. Competitive Intelligence Analysis for Neurogenic Detrusor Overactivity
  4. Neurogenic Detrusor Overactivity: Market Overview at a Glance

4.1. Neurogenic Detrusor Overactivity Total Market Share (%) Distribution in 2017

4.2. Neurogenic Detrusor Overactivity Total Market Share (%) Distribution in 2030

  1. Neurogenic Detrusor Overactivity: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

  1. Patient Journey
  2. Neurogenic Detrusor Overactivity Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Neurogenic Detrusor Overactivity Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Neurogenic Detrusor Overactivity Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Neurogenic Detrusor Overactivity Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Neurogenic Detrusor Overactivity Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Neurogenic Detrusor Overactivity Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Neurogenic Detrusor Overactivity Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Neurogenic Detrusor Overactivity Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Neurogenic Detrusor Overactivity Epidemiology Scenario in Japan (2017-2030)

  1. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Neurogenic Detrusor Overactivity Treatment and Management

8.2. Neurogenic Detrusor Overactivity Treatment Algorithm

  1. Unmet Needs
  2. Key Endpoints of Neurogenic Detrusor Overactivity Treatment
  3. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

  1. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

  1. Neurogenic Detrusor Overactivity: Seven Major Market Analysis

13.1. Key Findings

13.2. Neurogenic Detrusor Overactivity Market Size in 7MM

13.3. Neurogenic Detrusor Overactivity Market Size by Therapies in the 7MM

  1. Attribute analysis
  2. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Neurogenic Detrusor Overactivity Total Market Size in the United States

15.1.2. Neurogenic Detrusor Overactivity Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Neurogenic Detrusor Overactivity Total Market Size in Germany

15.3.2. Neurogenic Detrusor Overactivity Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Neurogenic Detrusor Overactivity Total Market Size in France

15.4.2. Neurogenic Detrusor Overactivity Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Neurogenic Detrusor Overactivity Total Market Size in Italy

15.5.2. Neurogenic Detrusor Overactivity Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Neurogenic Detrusor Overactivity Total Market Size in Spain

15.6.2. Neurogenic Detrusor Overactivity Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Neurogenic Detrusor Overactivity Total Market Size in the United Kingdom

15.7.2. Neurogenic Detrusor Overactivity Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Neurogenic Detrusor Overactivity Total Market Size in Japan

15.8.3. Neurogenic Detrusor Overactivity Market Size by Therapies in Japan

  1. Access and Reimbursement Overview of Neurogenic Detrusor Overactivity
  2. KOL Views
  3. Market Drivers
  4. Market Barriers
  5. Appendix

20.1. Bibliography

20.2. Report Methodology

  1. DelveInsight Capabilities
  2. Disclaimer

Request for detailed TOC: https://www.delveinsight.com/sample-request/neurogenic-detrusor-overactivity-market

Related Reports:

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

Media Contact
Company Name: 
DelveInsight Business Research LLP
Contact Person: 
Ankit Nigam
Email: [email protected]
City: 
Albany
State: New York
Country: 
United States
Website: https://www.delveinsight.com/

https://farmingsector.co.uk/

By sthakur